Catheter Ablation vs Antiarrhythmic Drug Therapy for Treatment of Premature Ventricular Complexes: A Systematic Review

Simple item page
dc.contributor.authorDe Silva, K.
dc.contributor.authorHaqqani, H.
dc.contributor.authorMahajan, R.
dc.contributor.authorQian, P.
dc.contributor.authorChik, W.
dc.contributor.authorVoskoboinik, A.
dc.contributor.authorKistler, P.M.
dc.contributor.authorLee, G.
dc.contributor.authorJackson, N.
dc.contributor.authorKumar, S.
dc.date.issued2023
dc.description.abstractThere is variability in treatment modalities for premature ventricular complexes (PVCs), including use of antiarrhythmic drug (AAD) therapy or catheter ablation (CA). This study reviewed evidence comparing CA vs AADs for the treatment of PVCs. A systematic review was performed from the Medline, Embase, and Cochrane Library databases, as well as the Australian and New Zealand Clinical Trials Registry, U.S. National Library of Medicine ClinicalTrials database, and the European Union Clinical Trials Register. Five studies (1 randomized controlled trial) enrolling 1,113 patients (57.9% female) were analyzed. Four of five studies recruited mainly patients with outflow tract PVCs. There was significant heterogeneity in AAD choice. Electroanatomic mapping was used in 3 of 5 studies. No studies documented intracardiac echocardiography or contact force-sensing catheter use. Acute procedural endpoints varied (2 of 5 targeted elimination of all PVCs). All studies had significant potential for bias. CA seemed superior to AADs for PVC recurrence, frequency, and burden. One study reported long-term symptoms (CA superior). Quality of life or cost-effectiveness was not reported. Complication and adverse event rates were 0% to 5.6% for CA and 9.5% to 21% for AADs. Future randomized controlled trials will assess CA vs AADs for patients with PVCs without structural heart disease (ECTOPIA [Elimination of Ventricular Premature Beats with Catheter Ablation versus Optimal Antiarrhythmic Drug Treatment]), with impaired LVEF (PAPS [Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy] Pilot), and with structural heart disease (CAT-PVC [Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease]). In conclusion, CA seems to reduce recurrence, burden, and frequency of PVCs compared with AADs. There is a lack of data on patient- and health care-specific outcomes such as symptoms, quality of life, and cost-effectiveness. Several upcoming trials will offer important insights for management of PVCs.
dc.description.statementofresponsibilityKasun De Silva, Haris Haqqani, Rajiv Mahajan, Pierre Qian, William Chik, Aleksandr Voskoboinik, Peter M. Kistler, Geoffrey Lee, Nicholas Jackson, Saurabh Kumar
dc.identifier.citationJACC: Clinical Electrophysiology, 2023; 9(6):873-885
dc.identifier.doi10.1016/j.jacep.2023.01.035
dc.identifier.issn2405-500X
dc.identifier.issn2405-5018
dc.identifier.orcidMahajan, R. [0000-0003-3375-5568]
dc.identifier.urihttps://hdl.handle.net/2440/139641
dc.language.isoen
dc.publisherElsevier
dc.rights© 2023 The American College of Cardiology Foundation. Published by Elsevier. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.jacep.2023.01.035
dc.subjectantiarrhythmic drug
dc.subjectcatheter ablation
dc.subjectpremature ventricular complex
dc.subjectventricular arrhythmia
dc.subjectventricular ectopy
dc.subject.meshHumans
dc.subject.meshHeart Diseases
dc.subject.meshVentricular Premature Complexes
dc.subject.meshAnti-Arrhythmia Agents
dc.subject.meshCatheter Ablation
dc.subject.meshProspective Studies
dc.subject.meshQuality of Life
dc.subject.meshUnited States
dc.subject.meshAustralia
dc.subject.meshFemale
dc.subject.meshMale
dc.titleCatheter Ablation vs Antiarrhythmic Drug Therapy for Treatment of Premature Ventricular Complexes: A Systematic Review
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications